Healthcare Industry News: Hansen Medical
News Release - September 16, 2013
Peter Osborne Joins myoscience as Chief Financial OfficerREDWOOD CITY, Calif., Sept. 16, 2013 -- (Healthcare Sales & Marketing Network) -- myoscience, inc. is pleased to announce the addition of Peter Osborne to the team as chief financial officer (CFO). Osborne has over 25 years of experience in high growth public and private companies, most notably with Hansen Medical and VNUS Medical Technologies, and most recently with SentreHEART, Inc.
Osborne led VNUS through dramatic revenue growth expanding to more than 350 employees and selling into more than 40 countries, culminating in its acquisition by Covidien in 2009. "It is exciting to be joining myoscience at this inflection point in their growth. The positive clinical benefits of Focused Cold TherapyTM experienced by patients and physicians is accelerating market adoption," said Osborne. "The current strategic needs of the company and my experience in fully realizing the value of innovative technologies fit perfectly to guiding the business to its next stage of commercial success."
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.